Enzene is a technology driven company based in Pune, India. We strive to harness disruptive innovation to enhance global health. Our aim is to provide, affordable, quality medicine for aiding lives with debilitating conditions.
Enzene has invested in world class R&D infrastructure which allow access to technologies of the future. Enzene has end to end development platform from our own propriety CHO duos cell lines, to high throughput upstream and downstream platforms, comprehensive drug product development capabilities backed by state of the art advanced analytical technologies supports speedy development of pre-clinical and clinical drug candidates.
We are pioneers in Continuous Bioprocess manufacturing and are capable of offering varied scientific support to our clients. Enzene CDMO provides access to an affordable, disruptive manufacturing platform for clinical candidates. Along with providing fully continuous end-end solutions, we also offer flexibility in terms of adapting to a fed-batch process.
Enzene has built technical expertise in terms of talent and infrastructure, which will allow us to deliver to the ever demanding needs of biosimilar market. Enzene’s core team has several years of experience working in both industry and academia at national and international level to develop cost effective therapeutics.
Our ultimate goal is to provide affordable healthcare to everyone who needs it!
Enzene is a subsidiary of Alkem Laboratories Ltd. Alkem is India’s generic & specialty pharmaceutical forerunner with global presence.
32% of Alkem’s revenue is generated via offshore sales. As well as they have consistently been ranked amongst the top ten pharmaceutical companies in India. Alkem has a strong portfolio with more than 800+ brands with more than 1,300 SKUs for a wide range of therapy segments which includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, Alkem’s dominance in the anti-infective segment has remained unchallenged.
Alkem has 21 manufacturing facilities at multiple locations in India and the United States of America. Their upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA – UK, SAHPRA-South Africa, TGA – Australia, ANVISA – Brazil, WHO – Geneva, TPD – Health Canada, PPB – Kenya, NDA – Uganda, MOH – Sudan, INVIMA – Colombia, TFDA – Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries.
Another feather in Alkem’s cap was added on December 23rd, 2015, when Alkem completed its Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited.
Enzene Bioscience Ltd., operates as an independent centre within Alkem Laboratories Ltd. Visit Alkem